Results show that elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rates with i-FACTOR vs. allograft.

The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption of clinical activities.

Funds will support studies of ALLOB allogeneic cell therapy to treat difficult tibial fractures and JTA-004 protein to treat for osteoarthritic knee pain.

Carmell will begin enrolling in a pivotal clinical program for Plasma-based Bioactive Material used in long-bone fractures as an adjunctive treatment.

This represents the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue.

New preclinical data confirms that local delivery of a bisphosphonate in combination with CERAMENT can regenerate cancellous bone.

InGeneron announces favorable study results using regenerative autologous adipose-derived cells that are prepared with the Transpose® RT System for treatment of partial-thickness rotator cuff tears.

BBS-Bioactive Bone Substitutes' patent application protecting ARTEBONE® bone graft substitute has been accepted in the U.S. 

Seikagaku and Eisai will co-develop and market knee osteoarthritis treatment SI-613 in China.